Cargando…

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors

Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in...

Descripción completa

Detalles Bibliográficos
Autor principal: Rizzo, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151905/
https://www.ncbi.nlm.nih.gov/pubmed/34066684
http://dx.doi.org/10.3390/medicina57050458
_version_ 1783698493782622208
author Rizzo, Alessandro
author_facet Rizzo, Alessandro
author_sort Rizzo, Alessandro
collection PubMed
description Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in approximately 50% of cases, and thus, molecularly targeted therapies have been actively explored in this setting. Among these, fibroblast growth factor receptor (FGFR) inhibitors have reported important results, as witnessed by the FDA approval of pemigatinib in previously treated metastatic CCA patients harboring FGFR2 fusion or other rearrangements. Herein, we provide an overview of available evidence on FGFR inhibitors in CCA, especially focusing on the development, pitfalls and challenges of emerging treatments in this setting.
format Online
Article
Text
id pubmed-8151905
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81519052021-05-27 Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors Rizzo, Alessandro Medicina (Kaunas) Review Despite advanced diseases continuing to be associated with grim prognoses, the past decade has witnessed the advent of several novel treatment options for cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous group of malignancies harboring potentially druggable mutations in approximately 50% of cases, and thus, molecularly targeted therapies have been actively explored in this setting. Among these, fibroblast growth factor receptor (FGFR) inhibitors have reported important results, as witnessed by the FDA approval of pemigatinib in previously treated metastatic CCA patients harboring FGFR2 fusion or other rearrangements. Herein, we provide an overview of available evidence on FGFR inhibitors in CCA, especially focusing on the development, pitfalls and challenges of emerging treatments in this setting. MDPI 2021-05-08 /pmc/articles/PMC8151905/ /pubmed/34066684 http://dx.doi.org/10.3390/medicina57050458 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rizzo, Alessandro
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title_full Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title_fullStr Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title_full_unstemmed Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title_short Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
title_sort targeted therapies in advanced cholangiocarcinoma: a focus on fgfr inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151905/
https://www.ncbi.nlm.nih.gov/pubmed/34066684
http://dx.doi.org/10.3390/medicina57050458
work_keys_str_mv AT rizzoalessandro targetedtherapiesinadvancedcholangiocarcinomaafocusonfgfrinhibitors